Overview

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy

Status:
Active, not recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

The purpose of the AveNEC trial is to investigate the clinical activity and safety of avelumab in patients with NEC G3 (WHO 2010), including "NET G3" who are progressive after first line chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Johannes Gutenberg University Mainz

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Antibodies, Monoclonal
Avelumab